Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commercial...
Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept data Givastomig, a potential...
FDA confirmed givastomig’s potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective response...
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment...
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet AMD,...
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around...
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line...
ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care...